Reconstituting human pancreatic cancer development for translational research

重建人类胰腺癌的发展以进行转化研究

基本信息

  • 批准号:
    9217005
  • 负责人:
  • 金额:
    $ 51.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-02-01 至 2020-01-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Pancreatic ductal adenocarcinoma (PDA) is almost universally lethal, reflecting its typical late-stage diagnosis, when effective treatment options are limited. Pancreatic intra-epithelial neoplasias (PanINs) represent an early, localized developmental stage of pancreatic ductal adenocarcinoma (PDA), when curative surgical resection remains feasible. Understanding features of PDA precursor lesions like PanINs could generate new strategies for early PDA diagnosis and intervention. We have created a novel system for genetic modification and growth of primary human pancreatic cells to reconstitute the development of lesions with molecular and pathological features of human PanINs. Upon orthotopic transplantation these immortalized clones produce stable human induced pancreatic intra-epithelial neoplasias (hiPanINs). Moreover, these PanIN lesions appear to be stable: after 6 months, they do not invade locally or metastasize. Here we propose to validate and optimize this new system for generating stable human PanIN-like lesions to enhance its uses for addressing unmet translational needs. In Aim 1 we propose to generate new hiPanIN clones whose mutational spectrum matches that found in native PanIN and PDA development. We will also assess prioritized biomarkers identified in the hiPanIN system in native human PanIN and PDA specimens. In Aim 2 we propose collaborative studies to test whether pancreatitis, further genetic modification, or extrinsic signals relevant to PDA can promote invasive or metastatic PDA in the hiPanIN orthotopic transplantation model. In summary our proposal is highly responsive to the FOA (PAR 16-059). We have created a “novel model to fill critical gaps in translational requirements” using “human and mammalian oncology models and their genetics”, and proposed studies to “ensure their appropriateness for addressing unmet translational needs.”
项目总结/摘要 胰腺导管腺癌(PDA)几乎普遍致命,反映了其典型的晚期 诊断,当有效的治疗选择有限。胰腺上皮内瘤变(PanIN) 代表胰腺导管腺癌(PDA)的早期局部发育阶段, 治愈性手术切除仍然可行。了解PDA前驱病变的特征, PanIN可以为早期PDA诊断和干预提供新的策略。我们创建了一个 用于遗传修饰和原代人胰腺细胞生长以重建人胰腺细胞的新系统 具有人PanIN的分子和病理学特征的病变的发展。原位时 移植这些永生化的克隆产生稳定的人诱导的胰腺上皮内 肿瘤(hiPanIN)。此外,这些PanIN病变似乎是稳定的:6个月后, 局部侵袭或转移。在这里,我们建议验证和优化这个新的系统, 稳定的人PanIN样病变,以增强其用于解决未满足的翻译需求的用途。目标1 我们建议产生新的hiPanIN克隆,其突变谱与在天然的hiPanIN中发现的突变谱相匹配。 PanIN和PDA开发。我们还将评估hiPanIN系统中识别的优先生物标志物 在天然人PanIN和PDA标本中。在目标2中,我们提出了合作研究,以测试是否 胰腺炎、进一步的基因修饰或与PDA相关的外在信号可以促进侵袭性或 hiPanIN原位移植模型中的转移性PDA。总之,我们的建议是高度 响应FOA(PAR 16-059)。我们创造了一个“新颖的模式,以填补翻译的关键空白, 使用“人类和哺乳动物肿瘤学模型及其遗传学”,以及拟议的研究 以“确保它们适合于解决未满足的翻译需求”。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Seung K Kim其他文献

Seung K Kim的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Seung K Kim', 18)}}的其他基金

Administrative and Biostatistics Core
行政和生物统计核心
  • 批准号:
    10187128
  • 财政年份:
    2021
  • 资助金额:
    $ 51.56万
  • 项目类别:
Administrative and Biostatistics Core
行政和生物统计核心
  • 批准号:
    10704093
  • 财政年份:
    2021
  • 资助金额:
    $ 51.56万
  • 项目类别:
Core C: CODEX Core
核心 C:CODEX 核心
  • 批准号:
    10704098
  • 财政年份:
    2021
  • 资助金额:
    $ 51.56万
  • 项目类别:
Core C: CODEX Core
核心 C:CODEX 核心
  • 批准号:
    10456775
  • 财政年份:
    2021
  • 资助金额:
    $ 51.56万
  • 项目类别:
Administrative and Biostatistics Core
行政和生物统计核心
  • 批准号:
    10456772
  • 财政年份:
    2021
  • 资助金额:
    $ 51.56万
  • 项目类别:
In vivo systems to discover mechanisms regulating human islet alpha cell function
体内系统发现调节人类胰岛α细胞功能的机制
  • 批准号:
    10623306
  • 财政年份:
    2020
  • 资助金额:
    $ 51.56万
  • 项目类别:
In vivo systems to discover mechanisms regulating human islet alpha cell function
体内系统发现调节人类胰岛α细胞功能的机制
  • 批准号:
    10228762
  • 财政年份:
    2020
  • 资助金额:
    $ 51.56万
  • 项目类别:
In vivo systems to discover mechanisms regulating human islet alpha cell function
体内系统发现调节人类胰岛α细胞功能的机制
  • 批准号:
    10441477
  • 财政年份:
    2020
  • 资助金额:
    $ 51.56万
  • 项目类别:
Therapeutic targeting of human islets with recombinant regulatory T cells
用重组调节性 T 细胞治疗人类胰岛
  • 批准号:
    10018894
  • 财政年份:
    2019
  • 资助金额:
    $ 51.56万
  • 项目类别:
Therapeutic targeting of human islets with recombinant regulatory T cells
用重组调节性 T 细胞治疗人类胰岛
  • 批准号:
    10450831
  • 财政年份:
    2019
  • 资助金额:
    $ 51.56万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.56万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了